CN105017149A - Substance with protein kinase inhibiting activity and preparation method therefor and application thereof - Google Patents
Substance with protein kinase inhibiting activity and preparation method therefor and application thereof Download PDFInfo
- Publication number
- CN105017149A CN105017149A CN201510303407.6A CN201510303407A CN105017149A CN 105017149 A CN105017149 A CN 105017149A CN 201510303407 A CN201510303407 A CN 201510303407A CN 105017149 A CN105017149 A CN 105017149A
- Authority
- CN
- China
- Prior art keywords
- compound
- protein kinase
- disease
- methylene dichloride
- dry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000001253 Protein Kinase Human genes 0.000 title claims abstract description 25
- 108060006633 protein kinase Proteins 0.000 title claims abstract description 25
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 239000000126 substance Substances 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 46
- 238000006243 chemical reaction Methods 0.000 claims abstract description 26
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 19
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims abstract description 18
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 10
- 150000003936 benzamides Chemical class 0.000 claims abstract description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 71
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 238000004821 distillation Methods 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 13
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 11
- 230000008482 dysregulation Effects 0.000 claims description 10
- 108091000080 Phosphotransferase Proteins 0.000 claims description 9
- 102000020233 phosphotransferase Human genes 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 239000012043 crude product Substances 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 239000012065 filter cake Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000012074 organic phase Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000010898 silica gel chromatography Methods 0.000 claims description 5
- 238000000967 suction filtration Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 208000016097 disease of metabolism Diseases 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 4
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 claims description 4
- 102000003916 Arrestin Human genes 0.000 claims description 3
- 108090000328 Arrestin Proteins 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
- 235000011152 sodium sulphate Nutrition 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 abstract 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000003909 protein kinase inhibitor Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 32
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 8
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 7
- 229960002584 gefitinib Drugs 0.000 description 7
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 7
- CZZZABOKJQXEBO-UHFFFAOYSA-N 2,4-dimethylaniline Chemical group CC1=CC=C(N)C(C)=C1 CZZZABOKJQXEBO-UHFFFAOYSA-N 0.000 description 6
- HXEWMTXDBOQQKO-UHFFFAOYSA-N 4,7-dichloroquinoline Chemical compound ClC1=CC=NC2=CC(Cl)=CC=C21 HXEWMTXDBOQQKO-UHFFFAOYSA-N 0.000 description 6
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 6
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 201000004101 esophageal cancer Diseases 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- -1 Naphthaline amide Chemical class 0.000 description 3
- 208000019065 cervical carcinoma Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- URLVCROWVOSNPT-XOTOMLERSA-N (2s)-4-[(13r)-13-hydroxy-13-[(2r,5r)-5-[(2r,5r)-5-[(1r)-1-hydroxyundecyl]oxolan-2-yl]oxolan-2-yl]tridecyl]-2-methyl-2h-furan-5-one Chemical compound O1[C@@H]([C@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCCCCC=2C(O[C@@H](C)C=2)=O)CC1 URLVCROWVOSNPT-XOTOMLERSA-N 0.000 description 1
- JCJUKCIXTRWAQY-UHFFFAOYSA-N 6-hydroxynaphthalene-1-carboxylic acid Chemical compound OC1=CC=C2C(C(=O)O)=CC=CC2=C1 JCJUKCIXTRWAQY-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- QUHYUSAHBDACNG-UHFFFAOYSA-N acerogenin 3 Natural products C1=CC(O)=CC=C1CCCCC(=O)CCC1=CC=C(O)C=C1 QUHYUSAHBDACNG-UHFFFAOYSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- URLVCROWVOSNPT-QTTMQESMSA-N desacetyluvaricin Natural products O=C1C(CCCCCCCCCCCC[C@@H](O)[C@H]2O[C@@H]([C@@H]3O[C@@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)=C[C@H](C)O1 URLVCROWVOSNPT-QTTMQESMSA-N 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a substance with protein kinase inhibiting activity and a preparation method therefor and an application thereof. The substance is a benzamide derivative and is specifically N-(2,4-dimethylphenyl)-4-[(7-chlorine-4-quinoline)amino]benzamide. The compound can be used as a protein kinase inhibitor and a histone deacetylase inhibitor, and used for treating a tumor; and a preparation reaction of the substance is low in cost and high in yield, and a reaction process is simple and easy to control, so that the preparation method is applicable to industrial production.
Description
Technical field
The invention belongs to field of medicaments, relate to a class new compound, the application in the preparation method being specifically related to a class benzamide derivatives (formula I) and this compound and the part disease medicament caused at preparation treatment protein kinase dysregulation thereof.
Background technology
Protein kinase is the phosphorylation in the class of enzymes of catalytic protein phosphorylation, particularly catalytic protein in specific tyrosine, Serine and threonine residues.Protein kinase all plays a key effect in the many cellular physiological processes of adjustment, comprises metabolism, cell proliferation, cytodifferentiation, cell survival, immunne response and vasculogenesis.
Protein kinase is divided into two classes usually, i.e. protein tyrosine kinase (PTKs) and serine-threonine kinase (STKs).Wherein protein tyrosine kinase can be divided into two classes again, i.e. non-transmembrane tyrosine kinase and the raw tyrosine kinase receptor of cross-film.At least determine at present 19 kinds of protein tyrosine kinase different subtribes, as EGF-R ELISA (EGFR), vascular endothelial growth factor receptor (VEGFR), Thr6 PDGF BB (PDGFR) and fibroblast growth factor receptor (FGFR).
Current research shows, numerous disease all regulates the cell response of the exception caused relevant with there being protein kinase.These diseases comprise inflammation, autoimmune disease, cancer, nervous system disorders and neurodegenerative disorders, cardiovascular disorder, metabolic disease, allergy, asthma and with hormone related condition (Tan, S-L, 2006, J.Immunol, 176:2872-2879; A.et al.2006, J.Immunol.177:1886-1893; Salek-Ardakani, S.et al.2005, J.Immunol.175:7635-7641; Kim, J.et al.2004, J.Clin.Invest., 114:823-827).Therefore, people are devoted to find the kinases inhibitor effectively can treating these diseases always.
International patent application WO2010139180A1 discloses structure and the synthetic method of the Naphthaline amide derivative serving of a kind of kinases inhibitor and NSC 630176, in this synthetic method: 1) the first step 6-hydroxynaphthoic acid and 4, the cesium carbonate of the one-tenth ether catalysts use of 7-dichloroquinoline, expensive, and toxicity is comparatively large, large to the pollution of environment; 2) severe reaction conditions, productive rate is lower.Therefore, the compound that this preparation method obtains is unsuitable for suitability for industrialized production.
Summary of the invention
The object of the invention is the technological deficiency for existing in prior art, a kind of antitumour activity is provided significantly to have the material of protein kinase inhibiting activity---benzamide derivatives, to excavate the drug candidate of the part disease that treatment protein kinase dysregulation causes.
First aspect present invention is to provide a kind of material with protein kinase inhibiting activity, for benzamide derivatives, described benzamide derivatives is N-(2,4-3,5-dimethylphenyl)-4-[(the chloro-4-quinoline of 7-) is amino] benzamide, and structural formula is such as formula shown in I:
This material is for structural formula is such as formula the geometrical isomer of compound shown in I and pharmacy acceptable salt thereof.
Second aspect present invention is to provide a kind of pharmaceutical composition, and it contains the pharmaceutical composition of above-mentioned compound, its geometrical isomer, its pharmacy acceptable salt, its hydrate or solvated compounds and pharmaceutically acceptable carrier or vehicle.
Third aspect present invention is to provide a kind of method preparing above-claimed cpd, and reaction equation is as follows:
Step (1):
Step (2):
Step (3):
The concrete operations of step (1) are: be dissolved in Virahol by compound ii and compound III, stirring and refluxing is after 5 hours, separate out pale yellow precipitate, after question response liquid is cooled to room temperature, evaporated under reduced pressure, residual solids washed with dichloromethane 3 times, collects filter cake, dry faint yellow solid powder IV.
The concrete operations of step (2) are: be dissolved in by compounds Ⅳ in dry methylene dichloride, stir, slowly drip sulfur oxychloride, dropwise rear backflow 4 hours in ice bath downhill reaction system, and underpressure distillation removing sulfur oxychloride, obtains compound V.
The concrete operations of step (3) are: be dissolved in by compound V in dry methylene dichloride, add compound VI, stir, the dry methylene chloride solution containing triethylamine is dripped under ice bath, 6-8 hour is reacted at 45 DEG C, TLC detects, after reacting completely, suction filtration removes most of salt, underpressure distillation, solid matter ethyl acetate/distilled water extracting and washing 3 times, merge organic phase, anhydrous sodium sulfate drying, underpressure distillation obtains crude product, silica gel column chromatography is separated (eluent is methylene dichloride: methyl alcohol=200:1), obtains target product I.
Described Virahol, sulfur oxychloride, triethylamine, ethyl acetate, anhydrous sodium sulphate, methyl alcohol Analysis about Selection are pure, and methylene dichloride Analysis about Selection is pure and dry anhydrous, and room temperature is 25 DEG C, and ice bath is 0-4 DEG C.
Fourth aspect present invention is to provide above-claimed cpd or aforementioned pharmaceutical compositions preparing the application in kinases inhibitor medicine and/or NSC 630176 medicine.
The disease that the purposes of arrestin kinases and/or histon deacetylase (HDAC) causes for treatment protein kinase dysregulation, the disease that described protein kinase dysregulation causes includes but not limited to cardiovascular disorder, metabolic disease, allergy, cancer and the disease relevant to hormone.
Compound of the present invention can the effect of effective arrestin kinase activity, thus has the part disease activity that potential treatment protein kinase dysregulation causes, can be used as the medicine of the part disease that protein kinase dysregulation causes.
First aspect of the present invention relates to the compound with protein kinase inhibiting activity, and the preparation method of this compound; Next relates to it and is preparing the application in the medicine for the treatment of the part disease that protein kinase dysregulation causes.
Compound anti-cancering activity of the present invention is obvious, and preparation method's cost is low, productive rate is higher, reaction process is simple and easy to control, is applicable to suitability for industrialized production.Compound of the present invention can be used for as Cardiovarscular, metabolic disease, allergy, cancer and the medicine with hormone related condition, particularly there is obvious anti-tumor activity, comprise human esophagus cancer ECA-109 cell, human lung cancer cell A549's cell, HeLa Cells and human liver cancer cells Hep G2 cell.
Embodiment
For many years, people be devoted to find always have protein kinase inhibiting activity and can treat and protein kinase activity exception relative disease micromolecular compound.The compound that bibliographical information is crossed has ring compound (US Patent No. 7,151,096), double-ring compound (US Patent No. 7,189,721), three ring compounds (US Patent No. 7,132,533), (2-oxyindole base-3-methylene radical) acetogenin (US Patent No. 7,179,910), the quinazoline compound (US Patent No. 7,098,330) etc. of pyrazolyl amido replacement, several kinases inhibitor is wherein had to be ratified for cancer therapy, as Glivec, Sutent and Sorafenib by FDA.Clinical effectiveness shows, compared with traditional chemotherapy, these medicines are with the obvious advantage.Excite people to improve methods for the treatment of based on the mechanism of these medicines thus, optimize compound molecule skeleton, find that there is the new compound that bioavailability is high, antitumour activity is obvious and toxicity is low.
The present invention's research synthesizes the material with protein kinase inhibiting activity---a kind of benzamide derivatives, this benzamide derivatives is N-(2,4-3,5-dimethylphenyl)-4-[(the chloro-4-quinoline of 7-) is amino] benzamide, its molecular formula is C
24h
20clN
3o, its structural formula is as shown in the formula I:
The compound of above formula structure can be used as kinases inhibitor and NSC 630176, is used for the treatment of the disease that protein kinase dysregulation causes.
The preparation method of the benzamide derivatives that the present invention relates to is as follows:
Following room temperature refers to 25 DEG C, and ice bath refers to 0-4 DEG C.
Step (1), by compound ii (4,7-dichloroquinoline) (5-20mmol) and compound III (para-amino benzoic acid) (5-20mmol) be dissolved in (20-50mL) in Virahol, stirring and refluxing (75-95 DEG C), after 5-7 hour, separate out pale yellow precipitate, after question response liquid is cooled to room temperature, evaporated under reduced pressure, residual solids washed with dichloromethane 3 times, collect filter cake, dry faint yellow solid powder IV (4-(7-chloroquinoline-4-is amino) phenylformic acid).
Reaction equation is as follows:
Step (2), the compounds Ⅳ that step (1) obtains is dissolved in dry methylene dichloride, stir, sulfur oxychloride (25-100mmol) is slowly dripped in ice bath downhill reaction system, dropwise rear backflow 3-5 hour, underpressure distillation removing sulfur oxychloride, obtains compound V (4-(7-chloroquinoline-4-is amino) Benzoyl chloride).
Reaction equation is as follows:
Step (3), the compound V (10-40mmol) that step (2) is obtained and compound VI (2, 4-xylidine) (5-20mmol) be dissolved in dry dichloromethane solution (10-40mL), stir, the dichloromethane solution (10-40mL) containing triethylamine (10-40mmol) is dripped under ice bath, 6-8 hour is reacted at 40-50 DEG C, TLC detects, after reacting completely, suction filtration removes most of salt, underpressure distillation obtains solid matter, use ethyl acetate/distilled water extracting and washing 3 times again, merge organic phase, anhydrous sodium sulfate drying, underpressure distillation obtains crude product, silica gel column chromatography is separated (eluent is methylene dichloride: methyl alcohol=200:1), obtain target product I.
Reaction equation is as follows:
For ensureing the purity of productive rate and the product reacted, preferably all Analysis about Selection is pure for Virahol, sulfur oxychloride, triethylamine, ethyl acetate, anhydrous sodium sulphate, methyl alcohol, and the best Analysis about Selection of methylene dichloride is pure and dry anhydrous.
Below in conjunction with specific embodiment, further illustrate content of the present invention, and the present invention is further elaborated, but these embodiments there is any restriction to the present invention absolutely not.Those skilled in the art under the enlightenment of this specification sheets to the embodiment of the present invention in any variation of doing all will belong in the scope of claims of the present invention.
Embodiment 1:
In the round-bottomed flask of 100mL drying, add 4,7-dichloroquinoline (0.985g, 5mmol), para-amino benzoic acid (0.685g, 5mmol) and Virahol 20mL, stir and make it fully dissolve.Slowly be warming up to 85 DEG C, after stirring and refluxing 5h, reaction solution separates out pale yellow precipitate, and TLC detection reaction balances, terminates reaction.After question response liquid is cooled to room temperature, evaporated under reduced pressure, residual solids 10mL washed with dichloromethane 3 times, collects filter cake, dry faint yellow solid powder 4-(7-chloroquinoline-4-is amino) phenylformic acid 1.40g, yield 95%.
Add containing 4-(7-chloroquinoline-4-is amino) phenylformic acid (1.491g in the round-bottomed flask of 100mL drying, dichloromethane solution 10mL 5mmol), stir, sulfur oxychloride (2.974g is slowly dripped in 0 DEG C of ice bath downhill reaction system, 25mmol), dropwise rear backflow (80 DEG C) 4 hours, underpressure distillation removing sulfur oxychloride, obtain 4-(7-chloroquinoline-4-is amino) Benzoyl chloride 1.431g, yield 91%.
Add containing 4-(7-chloroquinoline-4-is amino) Benzoyl chloride (1.581g in the round-bottomed flask of 100mL drying, 5mmol) and 2, 4-xylidine (0.605g, dry methylene chloride solution 10mL 5mmol), stir, slowly drip containing triethylamine (1.010g in 0 DEG C of ice bath downhill reaction system, dichloromethane solution 10mL 10mmol), react 7 hours at 45 DEG C, after TLC detection reaction is complete, suction filtration removes most of salt, underpressure distillation obtains solid matter, use ethyl acetate/distilled water extracting and washing 3 times again, merge organic phase, anhydrous sodium sulfate drying, underpressure distillation obtains crude product, silica gel column chromatography is separated (eluent is methylene dichloride: methyl alcohol=200:1), obtain target product N-(2, 4-3,5-dimethylphenyl)-4-[(the chloro-4-quinoline of 7-) is amino] benzamide 1.764g, yield 88%.
The target product of above-mentioned acquisition is carried out nucleus magnetic resonance, and nuclear magnetic data is as follows:
Hydrogen is composed:
1h-NMR (600MHz, DMSO, ppm):
δ9.74(s,1H),9.35(s,1H),8.58(d,J＝5.14Hz,1H),8.44(d,J＝8.99Hz,1H),8.04(d,J＝8.62Hz,2H),7.96(d,J＝2.02Hz,1H),7.62(dd,J＝2.02Hz,2.20Hz,1H),7.48(d,J＝8.44Hz,2H),7.22(d,J＝8.07Hz,1H),7.20(d,J＝5.32Hz,1H),7.08(s,1H),7.02(d,J＝7.89Hz,1H),2.29(s,3H),2.21(s,3H)；
Carbon is composed:
13c-NMR (150MHz, DMSO, ppm): δ 165.11,152.54,150.14,147.23,144.20,135.40,134.57,134.42,133.99,131.28,129.56,129.23,128.24,127.03,126.95,125.80,125.09,120.64,119.40,104.14,21.02,18.33; HRMS (+): m/z 402.1366 ([M+H]
+, C
24h
20clN
3oH
+calcd:402.1368)
High resolution: HRMS (+): m/z 402.1366 ([M+H]
+, C
24h
20clN
3oH
+calcd:402.1368)
Embodiment 2:
In the round-bottomed flask of 100mL drying, add 4,7-dichloroquinoline (1.970g, 10mmol), para-amino benzoic acid (1.372g, 10mmol) and Virahol 20mL, stir and make it fully dissolve.Slowly be warming up to 85 DEG C, after stirring and refluxing 5h, reaction solution separates out pale yellow precipitate, and TLC detection reaction balances, terminates reaction.After question response liquid is cooled to room temperature, evaporated under reduced pressure, residual solids 15mL washed with dichloromethane 3 times, collects filter cake, dry faint yellow solid powder 4-(7-chloroquinoline-4-is amino) phenylformic acid 2.751g, yield 92%.
Add containing 4-(7-chloroquinoline-4-is amino) phenylformic acid (2.982g in the round-bottomed flask of 100mL drying, dry methylene chloride solution 15mL 10mmol), stir, chloride containing sulfoxide (5.948g is slowly dripped in 0 DEG C of ice bath downhill reaction system, 50mmol), dropwise rear backflow (80 DEG C) 4 hours, underpressure distillation removing sulfur oxychloride, obtain compound 4-(7-chloroquinoline-4-is amino) Benzoyl chloride 2.799g, yield 89%.
Add containing compound 4-(7-chloroquinoline-4-is amino) Benzoyl chloride (3.162g in the round-bottomed flask of 100mL drying, 10mmol) and compound 2, 4-xylidine (1.211g, dry methylene chloride solution 20mL 10mmol), stir, slowly drip containing triethylamine (2.020g in 0 DEG C of ice bath downhill reaction system, dichloromethane solution 20mL 20mmol), react 8 hours at 45 DEG C, after TLC detection reaction is complete, suction filtration removes most of salt, underpressure distillation, solid matter ethyl acetate/distilled water extracting and washing 3 times, merge organic phase, anhydrous sodium sulfate drying, underpressure distillation obtains crude product, silica gel column chromatography is separated (eluent is methylene dichloride: methyl alcohol=200:1), obtain target product N-(2, 4-3,5-dimethylphenyl)-4-[(the chloro-4-quinoline of 7-) is amino] benzamide 3.409g, yield 85%.
The target product of above-mentioned acquisition is carried out nucleus magnetic resonance, and nuclear magnetic data is with embodiment 1, and by analysis, target product is N-(2,4-3,5-dimethylphenyl)-4-[(the chloro-4-quinoline of 7-) is amino] benzamide.
Experimental example: adopt tetrazolium (MTT) reduction method, measures the anti-tumor activity of N-(2,4-3,5-dimethylphenyl)-4-[(the chloro-4-quinoline of 7-) is amino] benzamide.
To take the logarithm cell in vegetative period, after adding 0.25% trysinization, add the RPMI-1640 substratum containing 10% calf serum, blow and beat into single cell suspension, be inoculated into 96 orifice plates with cell count 4000/hole, every hole adds substratum to 200 μ L, after cell dispersal is even, quiescent culture 24h, after cell is completely adherent, gives medicine (4 μm of olL of different concns respectively
-1, 8 μm of olL
-1, 16 μm of olL
-1and 32 μm of olL
-1, DMSO content is 1 ‰), positive controls gives the Gefitinib of same concentrations, and negative control group gives the DMSO of same volume, cultivates 24h, 48h and 72h respectively, and positive controls cultivates 72h.Then lucifuge adds 5mgmL
-1mTT (3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide bromine salt) 20 μ L, after continuing to cultivate 4h, abandon nutrient solution, every hole adds 150 μ L DMSO, concussion makes crystallisate fully dissolve, detect the absorbancy (A) at 490nm place by microplate reader, then calculate versus cell appreciation rate (RGR%), experiment repetition 3 times.The last half inhibiting rate (IC calculating the compounds of this invention and positive control drug Gefitinib according to Relative cell proliferation rate
50), the results are shown in Table 1.
This compound on tumor of table 1 cell and Normocellular half inhibiting rate
Note: n=3, compare with Gefitinib, a:P<0.01, b:P<0.001, SMMC7721 is human liver cancer cell, A549 is human lung carcinoma cell, and ECA-109 is human esophagus cancer cell, and HeLa is human cervical carcinoma cell, HUVEC is human umbilical vein endothelial cell, LO2 is Human normal hepatocyte, and MRC-5 is human embryonic lung fibroblast, and HEEC is people's microgliacyte.
Visible, the compounds of this invention N-(2,4-3,5-dimethylphenyl)-4-[(7-chloro-4-quinoline) amino] benzamide all has inhibit activities to human liver cancer cell, human lung carcinoma cell, human esophagus cancer cell, human cervical carcinoma cell, human umbilical vein endothelial cell, Human normal hepatocyte, human embryonic lung fibroblast, people's microgliacyte at interior cancer cells, and inhibition or suitable with positive control Gefitinib, or on Gefitinib.Especially to human liver cancer cell (SMMC-7721 cell), human lung carcinoma cell (A549 cell), human esophagus cancer cell (ECA-109 cell) and human cervical carcinoma cell (HeLa cell), half inhibiting rate is 1/7.5,1/21,1/10 and 1/14 of Gefitinib respectively, and that is the compounds of this invention is 7 times, 21 times, 10 times and 14 times of Gefitinib respectively to the inhibition of this several cancer cells.Table 1 data show the inhibition highly significant of the compounds of this invention to this several cancer cells, effectively can treat tumour.In addition, prepare compound reaction cost low, productive rate is high, and reaction process is simple and easy to control, and safe non-environmental-pollution, is applicable to suitability for industrialized production.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, under the premise without departing from the principles of the invention; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (10)
1. having a material for protein kinase inhibiting activity, is benzamide derivatives, and described benzamide derivatives is N-(2,4-3,5-dimethylphenyl)-4-[(the chloro-4-quinoline of 7-) is amino] benzamide, and structural formula is such as formula shown in I:
2. there is the material of protein kinase inhibiting activity according to claim 1, it is characterized in that, for structural formula is such as formula the geometrical isomer of compound shown in I and pharmacy acceptable salt thereof.
3. pharmaceutical composition, it contains the pharmaceutical composition of compound described in claim 1 or 2, its geometrical isomer, its pharmacy acceptable salt, its hydrate or solvated compounds and pharmaceutically acceptable carrier or vehicle.
4. prepare the method for compound described in claim 1 or 2, it is characterized in that, reaction equation is as follows:
5. method according to claim 4, it is characterized in that, the concrete operations of step (1) are: be dissolved in Virahol by Compound II per and compound III, stirring and refluxing, after 5 hours, separates out pale yellow precipitate, after question response liquid is cooled to room temperature, evaporated under reduced pressure, residual solids washed with dichloromethane 3 times, collects filter cake, dry faint yellow solid powder IV.
6. method according to claim 4 or 5, it is characterized in that, the concrete operations of step (2) are: compound IV be dissolved in dry methylene dichloride, stir, slowly sulfur oxychloride is dripped in ice bath downhill reaction system, dropwise rear backflow 4 hours, underpressure distillation removing sulfur oxychloride, obtains compound V.
7. according to the arbitrary described method of claim 4-6, it is characterized in that, the concrete operations of step (3) are: be dissolved in by compound V in dry methylene dichloride, add compound VI, stir, the dry methylene chloride solution containing triethylamine is dripped under ice bath, 6-8 hour is reacted at 45 DEG C, TLC detects, after reacting completely, suction filtration removes most of salt, underpressure distillation, solid matter ethyl acetate/distilled water extracting and washing 3 times, merge organic phase, anhydrous sodium sulfate drying, underpressure distillation obtains crude product, (eluent is methylene dichloride: methyl alcohol=200 in silica gel column chromatography separation
:1) target product I, is obtained.
8. according to the arbitrary described method of claim 4-7, it is characterized in that, described Virahol, sulfur oxychloride, triethylamine, ethyl acetate, anhydrous sodium sulphate, methyl alcohol Analysis about Selection are pure, and methylene dichloride Analysis about Selection is pure and dry anhydrous, room temperature is 25 DEG C, and ice bath is 0-4 DEG C.
9. pharmaceutical composition described in compound described in claim 1 or 2 or claim 3 is preparing the application in kinases inhibitor medicine and/or NSC 630176 medicine.
10. apply according to claim 9; it is characterized in that; the disease that the purposes of arrestin kinases and/or histon deacetylase (HDAC) causes for treatment protein kinase dysregulation, the disease that described protein kinase dysregulation causes includes but not limited to cardiovascular disorder, metabolic disease, allergy, cancer and the disease relevant to hormone.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510303407.6A CN105017149A (en) | 2015-06-04 | 2015-06-04 | Substance with protein kinase inhibiting activity and preparation method therefor and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510303407.6A CN105017149A (en) | 2015-06-04 | 2015-06-04 | Substance with protein kinase inhibiting activity and preparation method therefor and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105017149A true CN105017149A (en) | 2015-11-04 |
Family
ID=54407501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510303407.6A Pending CN105017149A (en) | 2015-06-04 | 2015-06-04 | Substance with protein kinase inhibiting activity and preparation method therefor and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105017149A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1321151A (en) * | 1998-10-01 | 2001-11-07 | 阿斯特拉曾尼卡有限公司 | Chemical compounds |
| US20070072862A1 (en) * | 2005-08-15 | 2007-03-29 | Dimauro Erin F | Bis-aryl amide compounds and methods of use |
| CN102775389A (en) * | 2012-04-05 | 2012-11-14 | 华侨大学 | Preparation method of N-substituted-4-(7-chloro-quinoline -4-amino)-benzamide derivatives, and application thereof |
| CN103724260A (en) * | 2013-12-18 | 2014-04-16 | 华侨大学 | Benzamide derivative and preparation method and application thereof |
| CN104030980A (en) * | 2014-06-10 | 2014-09-10 | 华侨大学 | N-(3-methoxyl-4-chlorphenyl)-4-[(7-chloro-4-quinoline) amino] benzamide, preparation and application thereof |
-
2015
- 2015-06-04 CN CN201510303407.6A patent/CN105017149A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1321151A (en) * | 1998-10-01 | 2001-11-07 | 阿斯特拉曾尼卡有限公司 | Chemical compounds |
| US20070072862A1 (en) * | 2005-08-15 | 2007-03-29 | Dimauro Erin F | Bis-aryl amide compounds and methods of use |
| CN102775389A (en) * | 2012-04-05 | 2012-11-14 | 华侨大学 | Preparation method of N-substituted-4-(7-chloro-quinoline -4-amino)-benzamide derivatives, and application thereof |
| CN103724260A (en) * | 2013-12-18 | 2014-04-16 | 华侨大学 | Benzamide derivative and preparation method and application thereof |
| CN104030980A (en) * | 2014-06-10 | 2014-09-10 | 华侨大学 | N-(3-methoxyl-4-chlorphenyl)-4-[(7-chloro-4-quinoline) amino] benzamide, preparation and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity | |
| CN110283162B (en) | A kind of epidermal growth factor receptor inhibitor and its application | |
| CN103288728A (en) | Naphthoyl amine derivative, and preparation method and application thereof | |
| CN102311395A (en) | Quinazoline ring substituted diphenylurea derivative and its purpose | |
| Ataollahi et al. | Novel quinazolinone derivatives as anticancer agents: Design, synthesis, biological evaluation and computational studies | |
| Xu et al. | New modification strategy of matrine as Hsp90 inhibitors based on its specific L conformation for cancer treatment | |
| CN102241726B (en) | Glycyrrhetinic acid derivative and application thereof as antitumor medicament | |
| CN110041222B (en) | Thymoquinone derivative, intermediate, preparation method and application thereof | |
| CN109053592B (en) | 1-(2,5-Dimethoxyphenyl)-3-(substituted pyrimidin-4-yl)urea compounds and their preparation and application | |
| CN108299398B (en) | Carbazole-containing quinazoline derivative with anti-tumor activity and pharmaceutical application thereof | |
| CN103351336A (en) | Naphthalenecarboxamide derivative as inhibitors of protein kinase and histone deacetylase and preparation method thereof | |
| CN106349224A (en) | JAK kinase inhibitor with 4-amino-(1H)-pyrazole structure and preparation method and application thereof | |
| CN110981882B (en) | Chelidonium nitric oxide donor derivatives, and preparation method and application thereof | |
| CN109053594B (en) | 1-(3,5-Dimethoxyphenyl)-3-(substituted pyrimidin-4-yl)urea compounds and their preparation and application | |
| CN105017149A (en) | Substance with protein kinase inhibiting activity and preparation method therefor and application thereof | |
| CN104817535A (en) | Quinolinone derivative, and synthetic method and application thereof | |
| CN103724260A (en) | Benzamide derivative and preparation method and application thereof | |
| CN103923004A (en) | Naphthalene formamide derivative and preparation and application thereof | |
| Lu et al. | Design, synthesis, and biological evaluation of novel trimethoxyindole derivatives derived from natural products | |
| CN112174958B (en) | A kind of pyrido[2,3-d]pyrimidine compound and its preparation method and use | |
| CN108558832A (en) | A kind of new type antineoplastic medicine Austria is uncommon for Buddhist nun's derivative and preparation method thereof | |
| CN102942552A (en) | 3,11-disubstituted-14-aryl-14H-dibenzo[a,j]xanthene derivatives, preparation methods and uses thereof | |
| CN106928224B (en) | Indoles Sophoridine derivative and preparation method thereof | |
| CN115304605B (en) | Oxetane derivatives with antitumor activity, and preparation method and application thereof | |
| CN111004220B (en) | 3- (4-phenyl-1H-2-imidazolyl) -1H-pyrazole compound, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151104 |